Introduction
For the first time in its history, the World Health Organization (WHO) has formally recommended the use of popular weight-loss medications for the treatment of obesity and type 2 diabetes. The announcement marks a major shift in global health policy, reflecting the rising urgency of tackling obesity-related diseases worldwide. Alongside this recommendation, WHO has emphasized the need to make cheaper generic versions of these medicines available to developing countries, where affordability remains a significant barrier.
Background: The Rise of Obesity and Diabetes
Obesity and diabetes are no longer considered problems of wealthy nations alone. With rapid urbanization, changing diets, and increasingly sedentary lifestyles, low- and middle-income countries are also facing a surge in these conditions.
- According to WHO estimates, more than 800 million people worldwide live with diabetes, while over 1 billion people are obese.
- Alarmingly, in 2021 alone, more than 3.7 million deaths were linked to obesity or overweight-related complications. This number surpasses the combined annual global deaths from malaria, tuberculosis, and HIV/AIDS.
These statistics underline why WHO’s recommendation is being seen as a landmark moment in the fight against chronic, non-communicable diseases.
The Medications in Focus
The drugs in question belong to a class known as GLP-1 receptor agonists (Glucagon-like peptide-1). Originally developed for the management of type 2 diabetes, these medications have shown strong secondary benefits in reducing appetite and promoting significant weight loss.
Among the most well-known brands are:
- Ozempic (semaglutide)
- Wegovy (semaglutide at higher doses)
- Mounjaro (tirzepatide)
These drugs help regulate blood sugar, suppress hunger, and improve overall metabolic health. While commonly called “weight-loss drugs,” they are more accurately therapies that treat both diabetes and obesity simultaneously.
High Cost and the Access Problem
One of the biggest hurdles with these medicines is their price. In the United States, for example, the monthly cost of semaglutide-based drugs can exceed $1,000 per patient. For low- and middle-income countries, this price point makes them almost completely inaccessible to the people who need them the most.
WHO has therefore called for immediate efforts to produce generic versions of these drugs. Generics are chemically identical to branded medicines but are sold at a fraction of the cost, once patents expire or are bypassed under international health provisions.
Experts believe that in countries like India, where large-scale pharmaceutical production is well established, these medicines could potentially be manufactured for as little as $4 per month, compared to the astronomical prices in Western markets.
Inclusion in WHO’s Essential Medicines List
In its latest update, WHO has added semaglutide and tirzepatide to its Essential Medicines List (EML) for adults. This catalog now contains 523 essential medicines for adults and 374 for children, representing the drugs that WHO believes should be available in every functioning healthcare system across the globe.
By including GLP-1 medications in this list, WHO is sending a clear signal to governments, donors, and pharmaceutical companies: these drugs are no longer considered luxury treatments for the wealthy, but life-saving interventions that should be accessible to all.
The Science Behind GLP-1 Drugs
GLP-1 receptor agonists mimic a natural hormone in the body that regulates blood sugar and appetite. By slowing digestion and increasing feelings of fullness, they help patients reduce food intake, leading to sustainable weight loss.
New studies are also revealing that the benefits extend beyond diabetes and obesity. For example:
- Research published in the medical journal JAMA found that heart patients taking semaglutide had a 40% lower risk of hospitalization or premature death.
- Preliminary studies suggest these drugs may also be useful in treating addiction disorders, given their effect on reward pathways in the brain.
Such findings make the case even stronger for expanding access, as the medications could help address multiple chronic health issues at once.
Patent Expiry and the Road to Generics
Patent laws have long been a roadblock for cheaper alternatives. However, starting next year, these medications will lose their patent protections in several markets, including India, China, and Canada. Once this happens, the production of generics will likely increase, dramatically lowering prices.
If generics are made widely available, millions of patients in developing countries could finally afford treatment. The challenge will then shift to ensuring distribution, awareness, and safe prescription practices.
A Turning Point in Public Health
WHO’s move has been welcomed by health experts and policymakers worldwide. By treating obesity not as a lifestyle issue but as a medical condition requiring intervention, WHO is attempting to reduce the stigma surrounding weight-loss medicines.
The decision also comes at a time when obesity is increasingly linked to other chronic illnesses, including heart disease, kidney failure, and certain cancers. Tackling obesity early can help reduce healthcare costs in the long run and improve quality of life for millions.
Concerns and Criticisms
Despite the optimism, some concerns remain:
- Affordability – Even if generics are produced, will governments subsidize them enough for poor patients?
- Overuse and misuse – With the drugs’ popularity rising, there is a risk of misuse by people seeking cosmetic weight loss rather than medical treatment.
- Side effects – GLP-1 drugs can cause nausea, gastrointestinal issues, and, in rare cases, more severe complications. Careful medical supervision is required.
- Equity – Wealthier populations may still benefit first, even in developing countries, unless proper policies ensure fair access.
Conclusion
WHO’s recommendation to include weight-loss drugs like Ozempic, Wegovy, and Mounjaro in its Essential Medicines List marks a pivotal moment in global health policy. With obesity and diabetes claiming millions of lives every year—more than malaria, tuberculosis, or HIV—the need for effective, affordable treatments has never been greater.
The real challenge now is ensuring that these drugs are not only recognized as essential but also made affordable and accessible worldwide, especially in poorer nations where the burden of obesity and diabetes is rapidly growing. If successful, the move could transform the lives of millions, turning the tide against two of the most pressing health challenges of our time.
